TO: Regulatory Information Service
PR Newswire
RE: PARAGRAPH 3.1.4 OF THE DISCLOSURE AND TRANSPARENCY RULES
The notifications listed below were all received under Paragraph 3.1.2 of the
Disclosure and Transparency Rules.
Diageo plc (the "Company") announces that:
1. it received notification on 14 April 2009 of the following allocations of
ordinary shares of 28 101/108 pence each in the Company ("Ordinary Shares")
under the Diageo Share Incentive Plan (the "Plan"), namely:
(i) the following directors of the Company were allocated Ordinary Shares on 14
April 2009 under the Plan, by Diageo Share Ownership Trustees Limited (the
"Trustee"):
Name of Director Number of Ordinary Shares
N C Rose 24
P S Walsh 24
(ii) the following "Persons Discharging Managerial Responsibilities" ("PDMR")
were allocated Ordinary Shares on 14 April 2009 under the Plan, by the Trustee:
Name of PDMR Number of Ordinary Shares
N Blazquez 24
S Fletcher 24
D Gosnell 24
J Grover 24
A Morgan 24
G Williams 24
I Wright 24
The number of Ordinary Shares allocated comprises those purchased on behalf of
the employee using an amount which the employee has chosen to have deducted
from salary ("Sharepurchase") and those awarded to the employee by the Company
("Sharematch") on the basis of one Sharematch Ordinary Share for every two
Sharepurchase Ordinary Shares.
The Sharepurchase Ordinary Shares were purchased and the Sharematch Ordinary
Shares were awarded at a price per share of £7.80.
The Ordinary Shares are held by the Trustee and in the name of the Trustee.
Sharepurchase Ordinary Shares can normally be sold at any time. Sharematch
Ordinary Shares cannot normally be disposed of for a period of three years
after the award date.
2. it received notification on 14 April 2009 from Dr F B Humer, a director of
the Company, that he had purchased 1,019 Ordinary Shares on 14 April 2009 under
an arrangement with the Company, whereby he has agreed to use an amount of £
8,000 each month, net of tax, from his director's fees to purchase Ordinary
Shares. Dr Humer has agreed to retain the Ordinary Shares while he remains a
director of the Company.
The Ordinary Shares were purchased at a price per share of £7.80.
3. it received notification on 14 April 2009 from Mr H T Stitzer, a director of
the Company, that he had purchased 128 Ordinary Shares on 14 April 2009 under
an arrangement with the Company, whereby he has agreed to use an amount of £
1,000 each month, net of tax, from his director's fees to purchase Ordinary
Shares.
The Ordinary Shares were purchased at a price per share of £7.80.
As a result of the above transactions, interests of directors and PDMRs in the
Company's Ordinary Shares (excluding options, awards under the Company's LTIPs
and interests as potential beneficiaries of the Company's Employee Benefit
Trusts) are as follows:
Name of Director Number of Ordinary Shares
Dr F B Humer 11,635
N C Rose 453,852
H T Stitzer 6,468
P S Walsh 719,833
Name of PDMR Number of Ordinary Shares
N Blazquez 43,255
S Fletcher 151,992
D Gosnell 59,446
J Grover 149,594
A Morgan 176,700
G Williams 243,794 (of which 5,916 are held as ADS
*)
I Wright 30,067
P D Tunnacliffe
Company Secretary
14 April 2009
*1 ADS is the equivalent of 4 Ordinary Shares.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.